CN103120702B - 包含疏水基团结合型糖胺聚糖在制备预防或治疗角膜上皮层病症的药物中的用途 - Google Patents

包含疏水基团结合型糖胺聚糖在制备预防或治疗角膜上皮层病症的药物中的用途 Download PDF

Info

Publication number
CN103120702B
CN103120702B CN201210562963.1A CN201210562963A CN103120702B CN 103120702 B CN103120702 B CN 103120702B CN 201210562963 A CN201210562963 A CN 201210562963A CN 103120702 B CN103120702 B CN 103120702B
Authority
CN
China
Prior art keywords
mucosa
gag
hydrophobic group
area
cinnamic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201210562963.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103120702A (zh
Inventor
宫本建司
高桥胜哉
下岛裕司
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seikagaku Corp
Original Assignee
Seikagaku Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seikagaku Corp filed Critical Seikagaku Corp
Publication of CN103120702A publication Critical patent/CN103120702A/zh
Application granted granted Critical
Publication of CN103120702B publication Critical patent/CN103120702B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CN201210562963.1A 2005-10-12 2006-10-12 包含疏水基团结合型糖胺聚糖在制备预防或治疗角膜上皮层病症的药物中的用途 Expired - Fee Related CN103120702B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2005297170 2005-10-12
JP2005-297170 2005-10-12
JP2006-160478 2006-06-09
JP2006160478 2006-06-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2006800380199A Division CN101287473B (zh) 2005-10-12 2006-10-12 包含疏水基团结合型糖胺聚糖在制备预防或治疗角膜上皮层病症的药物中的用途

Publications (2)

Publication Number Publication Date
CN103120702A CN103120702A (zh) 2013-05-29
CN103120702B true CN103120702B (zh) 2014-11-05

Family

ID=37942916

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201210562963.1A Expired - Fee Related CN103120702B (zh) 2005-10-12 2006-10-12 包含疏水基团结合型糖胺聚糖在制备预防或治疗角膜上皮层病症的药物中的用途
CN201210562380.9A Expired - Fee Related CN103120701B (zh) 2005-10-12 2006-10-12 包含疏水基团结合型糖胺聚糖在制备预防或治疗角膜上皮层病症的药物中的用途
CN2006800380199A Expired - Fee Related CN101287473B (zh) 2005-10-12 2006-10-12 包含疏水基团结合型糖胺聚糖在制备预防或治疗角膜上皮层病症的药物中的用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201210562380.9A Expired - Fee Related CN103120701B (zh) 2005-10-12 2006-10-12 包含疏水基团结合型糖胺聚糖在制备预防或治疗角膜上皮层病症的药物中的用途
CN2006800380199A Expired - Fee Related CN101287473B (zh) 2005-10-12 2006-10-12 包含疏水基团结合型糖胺聚糖在制备预防或治疗角膜上皮层病症的药物中的用途

Country Status (9)

Country Link
US (4) US20080306022A1 (cg-RX-API-DMAC10.html)
EP (1) EP1942912B1 (cg-RX-API-DMAC10.html)
JP (3) JP4387445B2 (cg-RX-API-DMAC10.html)
KR (4) KR101411067B1 (cg-RX-API-DMAC10.html)
CN (3) CN103120702B (cg-RX-API-DMAC10.html)
AU (1) AU2006300207C1 (cg-RX-API-DMAC10.html)
CA (1) CA2625532C (cg-RX-API-DMAC10.html)
ES (1) ES2616295T3 (cg-RX-API-DMAC10.html)
WO (1) WO2007043702A1 (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20080306022A1 (en) * 2005-10-12 2008-12-11 Kenji Miyamoto Agent for Applying to Mucosa and Method for the Production Thereof
KR101460815B1 (ko) 2006-12-06 2014-11-12 세이가가쿠 고교 가부시키가이샤 관절염 질환 치료의 지속성 효과를 갖는 제약 제제
JP2009046454A (ja) * 2007-08-22 2009-03-05 Shiseido Co Ltd 口腔内用組成物
ITMI20072237A1 (it) * 2007-11-27 2009-05-28 Sigea Srl Esteri misti butirrico-formico di polisaccaridi acidi, loro preparazione ed uso come dermocosmetici
JP5758797B2 (ja) 2008-04-04 2015-08-05 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション アルキル化半合成グリコサミノグリカンエーテルならびにその製造および使用方法
JP5542687B2 (ja) * 2008-11-05 2014-07-09 国立大学法人 東京医科歯科大学 ヒアルロン酸誘導体、およびその医薬組成物
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
CA2703532C (en) * 2010-05-10 2018-05-01 Eva Turley Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications
CA2830933A1 (en) 2011-03-23 2012-09-27 University Of Utah Research Foundation Methods for treating or preventing urological inflammation
US9067299B2 (en) 2012-04-25 2015-06-30 Applied Materials, Inc. Printed chemical mechanical polishing pad
CA2972212C (en) 2014-12-26 2024-10-29 Seikagaku Corporation AGENT AND IMPROVEMENT OF SUBJECTIVE OCULAR SYMPTOMS AND ASSOCIATED METHOD
CN104940221A (zh) * 2015-05-13 2015-09-30 北京大清生物技术有限公司 一种用于膀胱和尿道上皮损伤修复的组合物
US11253540B2 (en) 2015-05-29 2022-02-22 Seikagaku Corporation Composition including glycosaminoglycan derivative and chemokine receptor activity regulator
JP6757731B2 (ja) * 2015-08-20 2020-09-23 生化学工業株式会社 眼用デバイス適用剤
ES2979141T3 (es) * 2016-05-26 2024-09-24 Ophtecs Corp Preparación líquida para lentes de contacto que comprende derivado de ácido hialurónico hidrolizado y bactericida catiónico
WO2018053111A1 (en) 2016-09-15 2018-03-22 University Of Utah Research Foundation In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
ES2909998T3 (es) * 2016-10-14 2022-05-11 I Com Medical Gmbh Método para establecer, restablecer y preservar la homeostasis de la superficie ocular
JP7216006B2 (ja) 2017-03-22 2023-01-31 ジェネンテック, インコーポレイテッド ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
RU2652581C1 (ru) * 2017-07-03 2018-04-26 федеральное государственное бюджетное образовательное учреждение высшего образования "Приволжский исследовательский медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения роговично-конъюнктивального ксероза
CN111228653A (zh) 2018-11-13 2020-06-05 格莱科米拉治疗公司 用电离辐射加强癌症治疗的方法
JP7660066B2 (ja) 2019-10-03 2025-04-10 生化学工業株式会社 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602859B2 (en) * 2000-12-19 2003-08-05 Seikagaku Corporation Photocurable hyaluronic acid derivative and process for producing the same, and photocured crosslinked-hyaluronic acid derivative and medical material using the same

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
JPH0723317B2 (ja) * 1988-03-17 1995-03-15 生化学工業株式会社 角膜上皮層障害症治療剤
US5733892A (en) * 1990-07-24 1998-03-31 Seikagaku Corporation Metastasis inhibitor composition comprising a phospholipid-linked glycosaminoglycan and method for inhibiting metastasis employing the same
JP2855307B2 (ja) * 1992-02-05 1999-02-10 生化学工業株式会社 光反応性グリコサミノグリカン、架橋グリコサミノグリカン及びそれらの製造方法
DE4203529A1 (de) * 1992-02-07 1993-08-12 Wolff Walsrode Ag Wasserloesliche sulfoalkylhydroxyalkylderivate der cellulose und deren verwendung in gips- und zementhaltigen massen
ATE187821T1 (de) * 1994-03-14 2000-01-15 Seikagaku Kogyo Co Ltd Material zum tragen auf dem augapfel
US6025444A (en) * 1994-11-17 2000-02-15 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Cinnamic acid derivative
CA2162957C (en) * 1994-11-17 2011-08-02 Michinori Waki Cinnamic acid derivative
JP3308742B2 (ja) 1994-11-17 2002-07-29 生化学工業株式会社 光架橋性ヒアルロン酸誘導体とその架橋体およびそれらの製造方法
JP3955107B2 (ja) * 1995-05-01 2007-08-08 生化学工業株式会社 架橋多糖の製造法
US5789462A (en) * 1995-09-13 1998-08-04 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Photocured crosslinked-hyaluronic acid contact lens
JP4006039B2 (ja) * 1995-09-13 2007-11-14 生化学工業株式会社 光架橋ヒアルロン酸コンタクトレンズ
ES2179215T3 (es) * 1995-11-15 2003-01-16 Seikagaku Kogyo Co Ltd Gel de acido hialuronico con enlaces cruzados fotorreticulado y procedimiento para su preparacion.
EP0891775A4 (en) * 1996-12-27 2002-07-24 Seikagaku Kogyo Co Ltd MEDICINE FOR URBAN BLADDER DISORDERS
US6548487B2 (en) * 1996-12-27 2003-04-15 Seikagaku Corporation Agent for treatment of bladder troubles
JPH1171282A (ja) 1997-09-01 1999-03-16 Senju Pharmaceut Co Ltd 点眼用水性製剤
JP3014357B2 (ja) 1998-01-26 2000-02-28 生化学工業株式会社 角膜上皮層伸展促進剤
ITPD980169A1 (it) * 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
AU3327000A (en) * 1999-03-24 2000-10-09 Seikagaku Corporation Artificial saliva
PT1142566E (pt) 2000-04-07 2004-02-27 Medidom Lab Formulacao oftalmica topica na forma de uma solucao aquosa e uso de uma ciclosporina em associacao com acido hialuronico ou um de seus sais e com polisorbato 80
JP2001329002A (ja) * 2000-05-25 2001-11-27 Denki Kagaku Kogyo Kk 修飾ヒアルロン酸ゲルとその製造方法及びそれを含有する医用材料
JP2002037746A (ja) 2000-07-24 2002-02-06 Fuji Yakuhin:Kk キノロンカルボン酸系抗菌剤を含有する液剤
JP4172176B2 (ja) 2000-12-19 2008-10-29 生化学工業株式会社 光反応性ヒアルロン酸およびその製造方法ならびに光架橋ヒアルロン酸および医用材料
EP1353556A4 (en) * 2001-01-23 2009-09-09 Massachusetts Inst Technology SYNTHESIS OF HEPARIN AND OTHER GLYCOSAMINOGLYCANS IN SOLID PHASE AND SOLUTION PHASE
JP4273208B2 (ja) * 2001-03-30 2009-06-03 チッソ株式会社 婦人科疾患治療剤
WO2006030965A1 (en) * 2004-09-15 2006-03-23 Seikagaku Corporation Photoreactive polysaccharide, photocrosslinked polysaccharide products, the method of making them and medical materials therefrom
US20080306022A1 (en) * 2005-10-12 2008-12-11 Kenji Miyamoto Agent for Applying to Mucosa and Method for the Production Thereof
JP7023317B2 (ja) 2020-05-12 2022-02-21 沖電気工業株式会社 光波長フィルタ及び波長分離光回路

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602859B2 (en) * 2000-12-19 2003-08-05 Seikagaku Corporation Photocurable hyaluronic acid derivative and process for producing the same, and photocured crosslinked-hyaluronic acid derivative and medical material using the same

Also Published As

Publication number Publication date
CN103120701B (zh) 2014-11-05
KR101554834B1 (ko) 2015-09-21
KR20130109259A (ko) 2013-10-07
JP2009511423A (ja) 2009-03-19
CN101287473B (zh) 2013-01-02
CN103120701A (zh) 2013-05-29
KR101411067B1 (ko) 2014-06-27
WO2007043702A1 (en) 2007-04-19
AU2006300207C1 (en) 2012-05-24
US20080306022A1 (en) 2008-12-11
KR20080056012A (ko) 2008-06-19
JP5094799B2 (ja) 2012-12-12
US8969319B2 (en) 2015-03-03
KR20110120983A (ko) 2011-11-04
WO2007043702A9 (en) 2007-06-07
KR101428153B1 (ko) 2014-08-07
EP1942912A4 (en) 2010-10-06
US20150196574A1 (en) 2015-07-16
HK1184700A1 (en) 2014-01-30
CN101287473A (zh) 2008-10-15
EP1942912B1 (en) 2016-12-14
CN103120702A (zh) 2013-05-29
US20110207695A1 (en) 2011-08-25
US20180289730A1 (en) 2018-10-11
CA2625532A1 (en) 2007-04-19
JP4387445B2 (ja) 2009-12-16
CA2625532C (en) 2013-10-01
KR20140054368A (ko) 2014-05-08
ES2616295T3 (es) 2017-06-12
HK1184701A1 (en) 2014-01-30
JP2012211171A (ja) 2012-11-01
AU2006300207B2 (en) 2011-12-01
EP1942912A1 (en) 2008-07-16
AU2006300207A1 (en) 2007-04-19
JP2009298798A (ja) 2009-12-24

Similar Documents

Publication Publication Date Title
CN103120701B (zh) 包含疏水基团结合型糖胺聚糖在制备预防或治疗角膜上皮层病症的药物中的用途
JP3439481B2 (ja) 光架橋ヒアルロン酸ゲルおよびその製造法
US12558458B2 (en) Targeted in situ therapeutic delivery of secreted factors from stem cells for treatment of damaged tissue
Pescina et al. Permeation of proteins, oligonucleotide and dextrans across ocular tissues: experimental studies and a literature update
ES2905606T3 (es) Conjugados de hialuronano con sustancias farmacéuticamente activas, métodos y composiciones
CA2365767A1 (en) Angiogenesis inhibition
JP2009511423A5 (cg-RX-API-DMAC10.html)
CN119746037A (zh) 基于透明质酸的温敏型水凝胶sv@hp及其制备方法和应用
AU2012201314B2 (en) Agent for applying to mucosa and method for production thereof
HK1184701B (en) Use of glycosaminoglycan containing a binded hydrophobic group in the preparation of medicine for treating or preventing corneal epithelial layer disorders
HK1184700B (en) Use of glycosaminoglycan containing a binded hydrophobic group in the preparation of medicine for treating or preventing corneal epithelial layer disorders
CN118304485A (zh) 一种基于光固化水凝胶的泪小管栓塞的制备方法与应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1184701

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1184701

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141105

Termination date: 20181012